Venous thromboembolism is a frequent complication of total hip and knee replacement requiring prophylaxis with anticoagulants. A direct thrombin inhibitorximelagatran-did not show advantages over other anticoagulants and it was withdrawn from the market; however, new drugs are being developed. We conducted a systematic review and meta-analysis to identify conditions under which ximelagatran might potentially be superior to current standards. Medline, EMBASE, the Cochrane Library, and grey literature were screened for randomized trials comparing ximelagatran with warfarin or low-molecular-weight heparin for thromboprophylaxis in total hip or knee replacement. Two reviewers independently assessed and extracted data. A meta-analysis with especial attention to statistical heterogeneity was conducted. This study suggested that the risk-benefit profile of ximelagatran-and probably other similar agentsdepends on the type of surgery, the initial timing of administration, and probably the dose. These issues should be explicitly explored in future trials evaluating new direct thrombin inhibitors.
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Keywords: meta-analysis; prophylaxis; orthopedic surgery; venous thromboembolism; ximelagatran; direct thrombin inhibitors Background Venous thromboembolism (VTE)-comprising deep venous thrombosis (DVT) and pulmonary embolism (PE)-is the most frequent complication of major orthopedic surgery. Without the use of prophylaxis after total hip replacement (THR) or total knee replacement (TKR), the prevalence of venographic and proximal DVT diagnosed within 14 days after surgery might be as high as 85% and 36%, respectively, and although less certain, that of total and fatal PE might reach 28% and 7.5%, respectively, 1-6 and even after widespread use of thromboprophylaxis, the incidence of clinical symptomatic VTE after major orthopedic surgery remains high, being up to 2.8% at 91 days. 7 Current recommendations are to administer prophylaxis for at least 10 days, and if there is an excessive thrombosis risk, it is recommended to extend the duration. 2 Prophylactic strategies include the use of low-molecular-weight heparins (LMWHs), vitamin K antagonists (VKAs), and fondaparinux; however, they require either daily injections or frequent laboratory monitoring.
In recent years, a new class of orally administered direct thrombin inhibitors was introduced. The first agent in this class was ximelagatran (whose active form is melagatran), and it was the first oral anticoagulant agent to be developed in more than 50 years. It has a highly predictable plasma concentration after oral administration rapidly reaching therapeutic levels, a steady clearance pattern, and no significant pharmacological interactions, thus not needing laboratory monitoring. 8 Unfortunately, in spite of the initial promising results, it was recently withdrawn from all markets by the manufacturer due to the occurrence of severe hepatic toxicity. However, new drugs in the same class are currently being tested and due to the problems encountered with ximelagatran, carefully designed trials should be implemented. Although several reviews have been published [9] [10] [11] [12] [13] with the general conclusion of an overall lack of benefit derived from the use of ximelagatran, a careful evaluation of published studies might identify specific clinical situations in which ximelagatran could be beneficial.
Even though the general objective of a metaanalysis is to aggregate data from different studies to obtain a summary estimate of the effect of interest, pooling data is not always adequate and evaluation of heterogeneity becomes fundamental. 14, 15 The presence of statistical heterogeneity in a metaanalysis usually indicates clinical or methodological differences between the studies included, and therefore investigating the source of heterogeneity might help deciding the direction of future research or identifying potential subgroups of patients in whom the intervention might be more beneficial or harmful. 16 With this in mind, we conducted a systematic review and a meta-analysis of studies comparing ximelagatran with LMWH or warfarin for VTE prevention in patients undergoing major orthopedic surgery to identify the conditions under which ximelagatran might be superior and that should therefore be addressed in future trials of other oral direct thrombin inhibitors.
Methods

Search Strategy
We included randomized controlled studies comparing prophylaxis with ximelagatran given at a dose of 24 mg or more twice daily (the dose recommended by the manufacturer) with prophylaxis with either unfractionated heparin, or LMWH, or VKA for at least 7 days in patients undergoing THR or TKR.
The search was conducted in April 2005 using the following electronic databases from 1980 onward: MEDLINE, Excerpta Medica database (EMBASE), The Cochrane Database of Systematic Reviews, The Database of Abstracts of Reviews of Effects, The Cochrane Controlled Trials Register, and The Health Technology Assessment Database. Grey literature (eg, literature with limited distribution) was considered including the meeting abstracts of the International Society on Thrombosis and Haemostasis (1999 onward), the American Society of Hematology (1999 onward), the Web sites of the ximelagatran manufacturer (http://www.exanta. com), the Canadian Coordinating Office for Health Technology Assessment (http://www.ccohta.ca), and the Food and Drug Administration (FDA; http:// www.fda.gov). In addition, the lists of references of the retrieved journal articles were reviewed for cross-referencing. No language restrictions were considered. The search strategy for the MEDLINE and EMBASE databases, (using the OVID interface) is presented in eTable 1. For all other sources, the search terms used were melagatran and ximelagatran.
The references retrieved were assessed for possible inclusion based on the evaluation of the title and the abstract according to the aforementioned criteria. Letters to the editor, review articles, editorials, and commentaries were excluded and the remaining studies were fully assessed. We carefully sought for duplicate publications because it was likely that some of the studies were published in abstract form and as a full article.
Assessment of Study Quality and Data Extraction
Data extraction and quality assessment were done independently by 2 reviewers using a standardized electronic form, and discrepancies were resolved by consensus. The main outcome measures included the occurrences of (a) major VTE, defined as the occurrence of either proximal DVT or PE, assessed by an objective measurement technique (for DVT, venography or compression ultrasonography and for PE, computed tomography pulmonary angiography or ventilation perfusion scintigraphy scan, or pulmonary angiography) and (b) major bleeding episodes, defined as those bleeding episodes that were lethal or potentially lethal or severe enough to require surgery, blood transfusion, or hospital readmission, or those including hemorrhage in critical sites. The secondary outcome measures included the occurrences of (a) total venous thromboembolic events, defined as major VTE plus distal venous thrombosis, (b) symptomatic VTE events, and (c) any bleeding episode (including major and minor). However, because 2 studies did not report on the latter and the number of symptomatic events was very low, we did not perform further analyses.
Because the objective was to identify conditions under which patients might benefit from ximelagatran, several subgroup analyses were defined a priori according to the (a) type of surgery; (b) type of comparator; and (c) initial use of subcutaneous melagatran. To assess the robustness of the results, we conducted sensitivity analyses according to the (a) quality score of the study and adequacy of allocation concealment; (b) ximelagatran dose; (c) outcomes on intention-to-treat versus as-treatment groups; (d) timing of initiation of comparator, and (e) timing of initiation of melagatran/ximelagatran. Quality of the studies was assessed using the criteria proposed by Jadad and coworkers, 17 and we evaluated the adequacy of allocation concealment as appropriate or inappropriate according to the criteria proposed by Schulz and Grimes. 18 If information in the reports was insufficient for evaluation, these issues were recorded as unclear/unstated.
Statistical Analysis
For assessment of outcomes, a meta-analysis was conducted by calculating odds ratios (ORs) using a random-effects model according to the method described by DerSimonian and Laird. 19 Differences between effects were tested using a Z-test and P values < .05 were considered significant. Heterogeneity was calculated using the Cochran Q statistic 20 considering a P < .1 for the 2 as indicative of heterogeneity and the Higgins' I 2 statistic 21 for which heterogeneity was defined as low if < 25%, moderate if between 25% and 50%, or high if >50%. The possibility of publication bias was explored using inverted funnel plots of OR versus precision. All calculations were done using Review Manager (RevMan) release 4.2.7 (The Cochrane Collaboration, Oxford, United Kingdom).
Results
Literature Search Results
The review process is summarized in Figure 1 . The search yielded 187 potentially relevant studies of which 123 duplicates, letters, commentaries, reviews, eTable 1. Search Strategy for Medline and EMBASE using the OVID interface protocols, and editorials were excluded. The titles and abstracts of the 64 remaining studies were screened and 54 studies were further excluded because they did not meet the inclusion criteria. A total of 10 references were fully evaluated and 1 was excluded because it was a commentary. Therefore, 9 studies were included in the final review and meta-analysis. [22] [23] [24] [25] [26] [27] [28] [29] [30] All the information was extracted from the published reports in all but one case. Information from the EXULT B study was initially obtained from an abstract, 31 from the manufacturer Web site (http:// www.exanta.com), and from 3 FDA reports [32] [33] [34] because the full report had not been published at the time of the search; however, the results of this study were subsequently published 23 and information was updated accordingly, although no major discrepancies were found.
Characteristics of Included Studies
The 9 included studies randomized 13 756 patients whose distribution is shown in Table 1 . Of those, 1 study included only patients with THR, 4 included only patients with TKR, and 4 included both, and 3 studies used warfarin as a comparator, 6 used an LMWH (4 enoxaparin and 2 dalteparin), and 4 reported using subcutaneous melagatran initially. A total of 3 studies started melagatran/ximelagatran preoperatively and 6 postoperatively. Of the included studies, 2 were phase 2, dose-finding studies, 1 was a dose-response trial, and the remaining were doubleblind, double-dummy randomized controlled trials ( Table 2) . Across all studies, the operational definition of VTE and major bleeding as well as the inclusion criteria were virtually identical except for weight limitations in the phase 2 studies events. 
Methodological Quality
A total of 7 studies had a Jadad score of 5 and adequate allocation concealment. The phase 2 studies had Jadad scores of 2 and 3 and inappropriate allocation concealment. All the retrieved studies were industry-funded. We did not detect publication bias; however due to the small number of included studies, this cannot be completely ruled out.
Meta-analysis
A formal meta-analysis was conducted and the results are summarized in Table 3 . The initial meta-analysis including all studies showed no difference in the occurrence of major or total VTE between patients receiving ximelagatran and a comparator, and it suggested that patients receiving ximelagatran had an increased risk of major bleeding episodes; however, these results showed moderate-to-high statistical heterogeneity, and therefore further exploratory analyses were conducted receiving either ximelagatran or a comparator. The results suggested that there were no differences in the occurrence of total VTE or major bleeding events in patients receiving subcutaneous melagatran initially compared to those who did not receive it. Our results also suggested that the type of surgery was a major determinant of outcomes: among patients undergoing TKR, those who received ximelagatran had significantly fewer major and total All included studies used ximelagatran 24 mg bid with or without initial subcutaneous melagatran. f There were no studies evaluating warfarin in total hip replacement. No study used initial subcutaneous melagatran.
g These studies used ximelagatran 24 mg bid with or without initial subcutaneous melagatran. Only studies with a high Jadad score are included.
VTE events [major VTE: OR 0.68; 95% confidence interval (CI) 0.53, 0.89; P ¼ .004 and total VTE: OR 0.71; 95% CI 0.63, 0.80; P < .001] without an increase in major bleeding (OR 1.38; 95% CI 0.86, 2.22; P ¼ . 19 ), all of these results being statistically homogenous. In contrast, among patients undergoing THR, there were no differences in the occurrence of major VTE, total VTE, or major bleeding events between patients receiving ximelagatran and a comparator; however, all of these results showed high statistical heterogeneity receiving either ximelagatran or a comparator. Further analyses in patients who underwent THR showed that compared to LMWH, those who were started on melagatran/ximelagatran before surgery had fewer VTE events (major VTE: OR 0.32; 95% CI 0.19, 0.53; P < .001 and total VTE: OR 0.54; 95% CI 0.34, 0.84; P ¼ .006) but also an increase in major bleeding events (OR 3.33; 95% CI 1.88, 5.89; P < .001), whereas those who were started on the melagatran/ximelagatran after surgery had no difference in the occurrence of major VTE or major bleeding events and indeed they had more total VTE events than patients receiving LMWH (OR 1.49; 95% CI 1.22, 1.84; P < .001). Finally, when we analyzed the influence of the ximelagatran dose, we found that there were no differences in the occurrence of major VTE, total VTE, or major bleeding events in those patients receiving ximelagatran 24 mg bid whereas among patients receiving 36 mg bid there were fewer total VTE events without a difference in the occurrence of major VTE or major bleeding events. However, it needs to be noted that these analyses were restricted to patients undergoing TKR because all studies evaluating THR administered ximelagatran at a dose of 24 mg bid.
Discussion
In this study, we identified several areas that deserve further investigation in future trials evaluating new direct thrombin inhibitors for VTE prophylaxis in orthopedic surgery. In concordance with previously published studies, the overall results of our review showed that melagatran/ximelagatran was not superior to the comparators in terms of efficacy and that indeed it might be associated with a higher frequency of bleeding events. [9] [10] [11] [12] [13] However, the presence of significant statistical heterogeneity in the pooled estimates casts doubts on the appropriateness of combining such studies. It is worth mentioning that the Higgins' I 2 statistic is probably the most adequate way to assess statistical heterogeneity when a metaanalysis includes few studies because it describes the percentage of variability in the estimates that is due to real heterogeneity rather than sampling error. 21 A careful analysis of the source of the heterogeneity found in our results suggests that the risk benefit profile of ximelagatran depends on the type of surgery, the timing of administration of the first dose, and probably the dose, and it also suggests that initial administration of subcutaneous melagatran does not seem to provide an advantage in terms of efficacy. The importance of the type of surgery and initial timing of ximelagatran administration was evidenced when we conducted separate analysis for patients undergoing THR and TKR. In all subanalyses, the pooled effect estimates in patients undergoing TKR were statistically homogeneous (Q statistic > 0.10 and Higgins' I 2 < 25%) which suggests that there were no major differences between the studies. Among patients undergoing TKR, those starting melagatran/ximelagatran preoperatively had fewer major and total VTE events than those receiving LMWH with no associated increase in bleeding risk; however, among patients starting the drug postoperatively, there were no differences in the occurrence of major VTE, total VTE, or major bleeding events compared to patients receiving LMWH. The overall conclusion for TKR patients is that ximelagatran is at least as effective and safe as LMWH or warfarin for preventing VTE. Moreover, the subgroup analyses suggested that in TKR patients ximelagatran might even be superior if started preoperatively or if given at higher doses. In neither case was it associated with a higher bleeding risk.
In contrast, interpreting the results of patients undergoing THR is more difficult due to the fact that there was considerable statistical heterogeneity in most subanalyses, suggesting that there were methodological differences between the included studies. Subgroup analyses suggested that the heterogeneity found in THR patients could be explained, at least in part, by the initial timing of administration of ximelagatran. Our results showed that in THR patients receiving melagatran/ximelagatran preoperatively the risk of developing major or total VTE compared to LMWH was reduced by 68% and 46%, respectively; however, this reduction was associated with a 3.33-fold increase in the risk of developing major bleeding events. On the other hand, although THR patients starting melagatran/ ximelagatran postoperatively did not have an increase in the bleeding risk, they did not experience less major VTE events than those receiving LMWH and indeed had more total VTE events. In general, these results showed low-to-moderate heterogeneity. It is known that the timing of initiation of LMWH in relation to the surgery is an important factor influencing its efficacy and safety for VTE prophylaxis and 2 meta-analyses addressing this issue have been conducted. Hull and coworkers concluded that close proximity to surgery (6-8 hours postoperative) at half the usual daily dose was more effective than next day or 12 hours preoperative initiation of LMWH and safer than immediate (2 hours) preoperative administration. 35 However, Strebel and coworkers concluded that although perioperative regimens (within 12 hours of surgery) appeared to be more effective for preventing VTE than preoperative or postoperative LMWH regimens (>12 hours preoperative or postoperative), more major bleeding episodes were observed. 36 Our results are concordant with the latter study and we believe that the difference in the bleeding risk between THR and TKR patients might be due, at least in part, to intrinsic differences in the bleeding risk between both procedures, although it could also be the result of other unknown differences in study populations. Also in concordance with a previous study, 9 we found an increased occurrence of total VTE in THR patients when melagatran/ximelagatran was administered postoperatively. We believe that this might be due to the fact that this data are derived from 2 studies with different designs, and because it may be inappropriate to pool these studies, we cannot definitely conclude that postoperative melagatran/ximelagatran is inferior to LMWH in patients undergoing THR, although this is a strong possibility.
The limitations of the present study are those inherent to all meta-analyses, mainly its retrospective nature, and the fact that only a small number of studies were included. Furthermore, the use of several subgroup analyses supposes that the number of studies included in such analyses will be even smaller, thus raising concerns regarding generalizability. We acknowledge the fact that the available information does not show an adamant overall advantage of ximelagatran over current agents, but it has to be considered that only 5 of the included studies were designed to show superiority which might have resulted in an underpowered sample size. Finally, it is entirely possible that direct thrombin inhibitors are not really better than other anticoagulants, and that if they indeed have a higher antithrombotic efficacy, this could entail a higher bleeding risk.
Nevertheless, the aim of the current study was to make it hypothesis generating by finding situations where it is plausible that the use of ximelagatran-and presumably other agents in this class-might be superior to the current standards of practice and our findings should be interpreted with this in mind.
In summary, our results suggest that the efficacy and safety of ximelagatran-and possibly other direct thrombin inhibitors-might be related to the type of surgery and the initial timing of administration. It is possible that patients undergoing TKR are more likely to benefit from the use of direct thrombin inhibitors than patients undergoing THR. It is also possible that if these agents are started before TKR they might be superior to current standards. These issues should be specifically considered in the design and analysis of future studies evaluating new agents in this class.
